Press Releases Quoin Pharmaceuticals, Ltd.

Equities

QNRX

US74907L4095

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:30:00 10/07/2025 BST			5-day change	1st Jan Change
9.010 ^USD	-3.63%		+2.39%	-60.44%

07-08	Quoin Pharmaceuticals & CFO Gordon Dunn agree to a mutual separation	RE
07-08	Quoin Pharmaceuticals Ltd. Announces Mutual Separation with CFO Gordon Dunn	CI

Press Releases

Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases	06-26	AQ
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome	06-24	AQ
Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study	05-22	AQ
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome	05-20	AQ
Money Movers: HIT, SEPN, ALUR, LUCY, PRSO - Biotech, Healthcare, AI & Weight Loss Innovators Lead Momentum Surge - More Stocks Inside	05-15	AQ
Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study	05-14	AQ
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results	05-13	AQ
Quoin Pharmaceuticals to Announce First Quarter 2025 Financial Results on Tuesday, May 13, 2025	05-06	AQ
Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule	04-30	AQ
Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign	04-10	AQ
Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient	04-02	AQ
Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases	03-25	AQ
Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results	03-13	AQ
Quoin Pharmaceuticals to Announce Fourth Quarter and Full-Year 2024 Financial Results on Thursday, March 13, 2025	03-06	AQ
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications	03-04	AQ
Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study	02-27	AQ
Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome	02-25	AQ
Quoin Pharmaceuticals Launches ‘NETHERTON NOW’ Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure	02-04	AQ
Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome	01-23	AQ
Quoin Pharmaceuticals Announces Further Positive Clinical Data from Ongoing Pediatric Netherton Syndrome Study	01-14	AQ
PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials	01-07	AQ
Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study	01-06	AQ
Quoin Pharmaceuticals : Announces Pricing of $6.8 Million Public Offering Form 8 K	12-26	PU
Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering	12-20	AQ
Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study	12-19	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Quoin Pharmaceuticals, Ltd.

Equities

QNRX

US74907L4095

Biotechnology & Medical Research

Press Releases

Filters